Yunzhi Essence to Improve the Quality of Life of Patients With Advanced Stage of Cancer

Phase 2RecruitingNCT05754801

Chinese University of Hong Kong172 enrolled

Overview

A randomized, double-blinded, placebo-controlled clinical trial using a Chinese Medicine 'Coriolus Versicolor for improving the quality of life of patients with advanced-stage cancer. Subjects will be randomized into a treatment group or placebo group for 6 months.

According to the Compendium of Materia Medica, a classic encyclopedia for Chinese medicines written by the venerated Physician Li ShiZhen of the Ming dynasty, Yunzhi (Coriolus Versicolor) is treasured as a superbly valuable herb as it not only can strengthen and consolidate the body's resistance, as well as reinforce and nourish a person's marrow and kidney essence and also is harmless to patients. Recent research found that the extract from Yunzhi, named as polysaccharide-peptide (PSP), could inhibit the growth of human hematoma cell line \& sarcoma and was proved to have direct anti-cancer effects. Quality of life (QOL) of patients is the ultimate goal of palliative care as endorsed by the World Health Organization (WHO) in 1990. When survival is limited in advanced incurable diseases, quality of life is most important. Patients with advanced cancer (palliative) often manifest numerous physical and psychological symptoms and a poor quality of life. While maintenance of the quality of life of advanced cancer patients is important, the physical dimension of quality of life still needs improvement, especially in the palliative stage. To date, there is no specific supportive Traditional Chinese Medicine(TCM)-related products that have been proven in randomized controlled trials for alleviating these debilitating symptoms and improving their quality of life. The present study aims to scientifically evaluate whether a Yunzhi product named G.E. Yunzhi-Essence is effective and safe in improving the QOL of palliative patients with advanced cancer.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

TRIPLE

Enrollment

172

Conditions

Cancer Palliative Care

Interventions

Yunzhi EssenceDRUG

Yunzhi Essence capsule

PlaceboOTHER

Placebo capsules

Eligibility

Sex: ALLMin age: 21 YearsMax age: 89 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed with advanced cancer according to the definition from American Cancer Society; * According to the experience of the doctor, by using Palliative Prognostic Index (score\>4), integrated with past cases and professional knowledge judged to have life expectancy not less than six months to two years; * Abbreviated mental test (AMT) score of 6 or above; * Voluntarily participate in this clinical trial and sign the informed consent form (acceptance of close relatives signed informed consent on behalf of the patient); * Refer to the national standard for Clinic terminology of traditional Chinese medical diagnosis and treatment-Part 2:Syndromes/patterns, syndrome of "damp heat spleen" and "spleen deficiency with water stop" (Fulfill 2 of the main symptoms and 2 of the secondary symptoms). Exclusion Criteria: * Patients with a history of allergy to traditional Chinese medicine or Yunzhi; * Patients who required nasal feeding or difficulty swallowing; * Patients with comatose/semi-conscious, cognitively impaired with dementia/confusion, physically too ill with extremely poor general condition, or there was a language barrier.

Locations (1)

School of Chinese Medicine

Hong Kong, Hong Kong

RECRUITING

Outcomes

Primary Outcomes

Score change of McGilll QOL-Hong Kong

McGill QOL-Hong Kong questionnaire will be used to measure the quality of life of subjects. It consists of 16 items and also a single item rating the overall QOL. All the response categories are based on a numerical scale from 0 to 10, with verbal anchors at the ends of the scale. The higher the score, the better the quality of life.

Time frame: 6 months

Secondary Outcomes

Survival rate

Survival rate will be measured from baseline to month 6

Time frame: From baseline to 6 months

Changes in immunological levels

T Serum immunoglobulins levels such as immunoglobulin A (IgA), immunoglobulin G (IgG) and immunoglobulin M (IgM) are key immunological markers for the humoral immune status. The levels of IgA, IgG and IgM are determined routinely in clinical practice to give the doctors important information about the immune system function, especially relating to infection or autoimmune diseases.

Time frame: 4 months

Changes in immunological levels

Time frame: 6 months

Changes in tumor marker level

When cancer occurs, a substance called "tumor marker" will appear in the body. It may be a by-product of cancer cells or the body's response to the tumor. Most tumor markers are proteins that can be detected in blood or urine come out. Tumor markers help to determine the possibility of cancer in some patients. One of the most important uses of tumor markers is to monitor the progress of patients during treatment. The blood sample will be taken for measuring the tumor marker on month 4.

Central Contacts

Cho Wing Lo

CONTACT

35053476 louislo@cuhk.edu.hk

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Time frame: 4 months

Changes in tumor marker level

Time frame: 6 months

Score change of Edmonton Symptom Assessment System (ESAS)

The ESAS includes 11 common patient symptoms: pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, sleep, well-being, shortness of breath, and "other". It uses a 0-10 numerical scale: 0 indicates the absence of a symptom, and 10 indicates the worst experience of the symptom.

Time frame: 6 months

Use of rescue pain medication

Number of rescue pain medication will be record during the study period

Time frame: From baseline to 6 months

Number of interventional medical treatments

Total number of interventional medical treatment will be records during the study period

Time frame: From baseline to 6 months

Level change of total bilirubin

Blood samples will be taken for Liver function test(LFT). Total bilirubin will be measured.

Time frame: From baseline to 6 months

Level change of Alkaline Phosphatase (ALP)

Blood samples will be taken for Liver function test(LFT). Alkaline Phosphatase (ALP) will be measured.

Time frame: From baseline to 6 months

Level change of Alanine Transaminase (ALT)

Blood samples will be taken for Liver function test(LFT). Alanine Transaminase (ALT) will be measured.

Time frame: From baseline to 6 months

Level change of Aspartate Transferase (AST)

Blood samples will be taken for Liver function test(LFT). Aspartate Transferase (AST) will be measured.

Time frame: From baseline to 6 months

Level change of Gamma-glutamyl Transferase (GGT)

Blood samples will be taken for Liver function test(LFT). Gamma-glutamyl Transferase (GGT) will be measured.

Time frame: From baseline to 6 months

Level change of Creatinine

Blood samples will be taken for Renal function test (RFT). Creatinine will be measured.

Time frame: From baseline to 6 months

Level change of Sodium

Blood samples will be taken for Renal function test (RFT). Sodium will be measured.

Time frame: From baseline to 6 months

Level change of Potassium

Blood samples will be taken for Renal function test (RFT). Potassium will be measured.

Time frame: From baseline to 6 months

Level change of Blood urea nitrogen (BUN)

Blood samples will be taken for Renal function test (RFT). Blood urea nitrogen (BUN) will be measured.

Time frame: From baseline to 6 months

Level change of Uric acid

Blood samples will be taken for Renal function test (RFT). Uric acid will be measured.

Time frame: From baseline to 6 months

Level change of blood markers

Blood samples will be taken for Complete blood count (CBC)

Time frame: From baseline to 6 months

Change of urine analysis

Urine sample will be taken for urine protein analysis.

Time frame: 2 months

Change of urine analysis

Urine sample will be taken for urine protein analysis.

Time frame: 4 months

Change of urine analysis

Urine sample will be taken for urine protein analysis.

Time frame: 6 months

Change in body weight

Body weight will be measure during each visit

Time frame: From baseline to 6 months

Number of oral ulcer

Total number of oral ulcer during study period

Time frame: From baseline to 6 months

Change in Chinese medicine symptom score

Chinese medicine practitioners will assess subjects' symptoms in month 2, the symptoms such as bloating, less appetite, fatigue and defecation. The symptoms will be scored on a scale of 0,2,4,6, which represents none, mild, moderate and severe respectively. A higher score means a worse outcome.

Time frame: 2 months

Change in Chinese medicine symptom score

Chinese medicine practitioners will assess subjects' symptoms in month 4, the symptoms such as bloating, less appetite, fatigue and defecation. The symptoms will be scored on a scale of 0,2,4,6, which represents none, mild, moderate and severe respectively. A higher score means a worse outcome.

Time frame: 4 months

Change in Chinese medicine symptom score

Chinese medicine practitioners will assess subjects' symptoms in month 6, the symptoms such as bloating, less appetite, fatigue and defecation. The symptoms will be scored on a scale of 0,2,4,6, which represents none, mild, moderate and severe respectively. A higher score means a worse outcome.

Time frame: 6 months